Skip to main content
DBVT
NASDAQ Life Sciences

Baker Bros. Advisors Exercises Warrants, Maintains Near-10% Stake in DBV Technologies

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.34
Mkt Cap
$695.035M
52W Low
$3.8
52W High
$26.185
52W Position info
356% above low
Off High info
34% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

DBVT has more than doubled off its 52-week low of $3.8.

Summary

Baker Bros. Advisors, a significant institutional investor, exercised expiring warrants into new pre-funded warrants, committing substantial capital to maintain its near-10% beneficial ownership in DBV Technologies S.A.


Key Events · Ownership and Investor Activity · DBVT

  • Warrant Exercise

    Baker Bros. Advisors' managed funds exercised 27.3 million BS Warrants into Second Pre-Funded Warrants, which are exercisable for 1.75 Ordinary Shares each.

  • Significant Capital Commitment

    The exercise of the BS Warrants involved a cash outlay of approximately EUR 43.1 million (or ~$46.5 million USD).

  • Strategic Position Maintained

    The move allows Baker Bros. to maintain its beneficial ownership at 9.99% of DBV Technologies, subject to regulatory limitations for full share conversion.

  • Post-Clinical Milestone

    The exercise occurred shortly after the VITESSE Phase 3 study met its primary endpoint, indicating continued confidence in the company's prospects.


Analysis · DBVT · Life Sciences

This Schedule 13D/A filing reveals a significant strategic move by Baker Bros. Advisors, a prominent biotech investor. By exercising expiring BS Warrants into new Second Pre-Funded Warrants, Baker Bros. has committed substantial capital to maintain its influential near-10% stake in DBV Technologies. This action, taken shortly after positive Phase 3 clinical trial results for the VITESSE study, signals strong, continued conviction in the company's long-term potential. While the full conversion to ordinary shares remains subject to beneficial ownership limitations, this restructuring of their holdings demonstrates a strategic commitment to their investment, which could be viewed positively by the market.

At the time of this filing, DBVT was trading at $17.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695M. The 52-week trading range was $3.80 to $26.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DBVT - Latest Insights

DBVT
Jul 27, 2026, 7:46 AM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $13.77
Real-time Price: $13.85 info
Change: +$0.080 (+0.58%) info
Market Cap: $800.711M info
DBVT
Jul 16, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.86
Real-time Price: $13.85 info
Change: -$1.01 (-7%) info
Market Cap: $800.711M info
DBVT
Jul 16, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.86
Real-time Price: $13.85 info
Change: -$1.01 (-7%) info
Market Cap: $800.711M info
DBVT
Jun 29, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.00
Real-time Price: $13.85 info
Change: -$2.15 (-13%) info
Market Cap: $800.711M info
DBVT
Jun 05, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.59
Real-time Price: $13.85 info
Change: -$2.74 (-17%) info
Market Cap: $800.711M info